0001437749-26-016429
SEC filingElectromed delivered robust Q3 results with revenue acceleration from sales force expansion and productivity gains, driving dramatic profitability improvements through operating leverage while generating strong cash flows to support operations and future needs.
Gross profit reached $14.6 million, a 19.7% increase from $12.2 million, achieving a robust 78.8% gross margin. This expansion demonstrates effective cost management and the benefits of scale in the company's core airway clearance therapy business, where higher revenues amplified profitability without proportional cost increases.
Operating income more than doubled to $3.8 million, up 76.0% from $2.1 million, delivering a 20.3% operating margin. The leverage from revenue growth significantly outpaced operating expenses, enabling substantial margin expansion. This performance highlights the efficiency of Electromed's homecare-focused model, where sales productivity gains directly enhance bottom-line results.
Net income advanced 58.8% to $3.0 million, with diluted EPS rising 66.7% to $0.35 from $0.21. These gains reflect the flow-through of improved operating results, positioning the company for continued earnings momentum.
Growth in the quarter also reflects an increase in sales representatives focused on the hospital market and higher capital and disposal demand, contributing to overall revenue momentum. Decreases in other revenue were due to lower demand from international distributors. The company anticipates accelerating remaining tax deductions over 2026, providing additional cash flow support. This positions Electromed with financial flexibility amid its sales-driven expansion strategy.